Improper title.<p>1. This is specifically about non-SCLC.<p>2. This article is entirely about a <i>downside</i> to receiving PD-1/PDL-1 inhibitor biologics as immunotherapy; that approximately a third of patients develop HPD and should be switched to salvage chemotherapy as soon as this is noted.